Sugi Predict

Sugi Predict / Compounds / SCHEMBL458559

SCHEMBL458559

SCHEMBL458559

O=C(O)c1ccc(OCC(F)(F)F)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 1.00
▸ MAPT P10636 3/20 0.63
▸ POLB P06746 1/20 0.63
▸ MAPK1 P28482 1/20 0.63
▸ EPHX2 P34913 4/20 0.57
▸ CYP2C9 P11712 2/20 0.55
▸ CYP2C19 P33261 2/20 0.55
▸ CYP2J2 P51589 1/20 0.55
▸ SCN9A Q15858 1/20 0.52
▸ DGAT1 O75907 2/20 0.49
▸ MRGPRX4 Q96LA9 1/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ CYP1A2 P05177 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ P4HA1 P13674 1/20 0.47
▸ P4HTM Q9NXG6 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29488316 1.00 L3MBTL1 (1.00) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL2713327 0.87 L3MBTL1 (0.77) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL2714708 0.87 L3MBTL1 (0.77) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL796847 0.86 L3MBTL1 (0.76) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL4797055 0.85 L3MBTL1 (0.74) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL2185157 0.85 L3MBTL1 (0.74) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL8692023 0.85 L3MBTL1 (0.74) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL796127 0.85 L3MBTL1 (0.74) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL2714985 0.84 L3MBTL1 (0.73) L3MBTL1MAPTPOLBMAPK1EPHX2
SCHEMBL9147122 0.84 L3MBTL1 (0.73) L3MBTL1MAPTPOLBMAPK1EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 190 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2908843-B1 TREATING CANCER AGENCY SCIENCE TECH & RES (SG) 2019-09-04 — — EP claimed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 — — EP disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 — — US disclosed
CN-112204009-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2024-05-07 — — CN disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 — — US disclosed
EP-3452456-B1 BICYCLIC MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2023-07-05 — — EP disclosed
US-20230086702-A1 SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2023-03-23 — — US disclosed
CN-109641854-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-02-03 — — CN disclosed
US-20220289685-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2022-09-15 — — US disclosed
EP-4017591-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES UCB Biopharma SRL (BE) 2022-06-29 — — EP disclosed
WO-2004048319-A1 NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS 7TM PHARMA A/S (DK) 2004-06-10 — — WO disclosed
WO-2004032908-A9 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LAB (US) 2004-05-27 — — WO disclosed
WO-2004032908-A2 METHOD OF INHIBITING ANGIOGENESIS ABBOTT LABORATORIES (US) 2004-04-22 — — WO disclosed
US-20040067985-A1 Method of inhibiting angiogenesis ABBOT LABORATORIES 2004-04-08 — — US disclosed
WO-2003087045-A1 NOVEL METHOXYBENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS 7TM PHARMA A/S (DK) 2003-10-23 — — WO disclosed
EP-1257536-A1 SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF Cytovia, Inc. (US) 2002-11-20 — — EP disclosed
US-20020010185-A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof CYTOVIA, INC. 2002-01-24 — — US disclosed
WO-2001055115-A1 SUBSTITUTED NICOTINAMIDES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF CYTOVIA, INC. (US) 2001-08-02 — — WO disclosed
EP-1091958-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2001-04-18 — — EP disclosed
WO-2000001692-A1 SALTS OF PAROXETINE SMITHKLINE BEECHAM PLC (GB) 2000-01-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220289685-A1 ANTIMALARIAL HEXAHYDROPYRIMIDINE ANALOGUES G6PD, DPYD, DHFR L3MBTL1 640/4885MAPT 2988/4885POLB 771/4885
US-20020010185-A1 Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof CASP3, BAD, CASP12 L3MBTL1 2930/4885MAPT 4426/4885POLB 2535/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 L3MBTL1 1651/4885MAPT 3293/4885POLB 1764/4885
US-20040067985-A1 Method of inhibiting angiogenesis VEGFA, PGF, FLT4 L3MBTL1 4485/4885MAPT 4658/4885POLB 1457/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R L3MBTL1 3261/4885MAPT 387/4885POLB 2718/4885
US-20230086702-A1 SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND USE THEREOF SNCA, PSEN2, PRNP L3MBTL1 2687/4885MAPT 7/4885POLB 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.